If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 41 - 50 of 270
A Randomized Phase III Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Objective
Trial of Zanubrutinib in older patients with mantle cell lymphoma
Protocol No
ALLIANCE-A052101
Categories
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Objective
A Phase 1b/2a Study of GNS561 in Combination with Trametinib in
Advanced KRAS Mutated Cholangiocarcinoma
Advanced KRAS Mutated Cholangiocarcinoma
Protocol No
GENFIT-GNS561-222-1
A Phase 1, Dose-Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity
Objective
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adults
Protocol No
DEBIOPHARM-DEBIO0123-102
Categories
A Phase 2 , Open-Label, Multicenter, Randomized Study Evaluating Neoadjuvant Therapy Targeting the Adenosine Immunosuppressive Pathway in Combination with Immune Checkpoint Blockade and Radiation Therapy in Patients with Advanced PANCreatic Ductal Ad
Objective
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma (AIRPanc)
Protocol No
COLUMBIA-AAAU4206-AIRPANC
Categories
Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma (HCC)
Objective
Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)
Protocol No
ABK-CA-PROT-85
Categories
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Objective
Testing the role of DNA released from tumor cells into the blood in guiding the use of immunotherapy after surgical removal of the bladder for bladder cancer treatment.
Protocol No
ALLIANCE-A032103-MODERN
Categories
A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination with Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma a
Objective
ASP2138 in Adults With Stomach Cancer or Pancreatic Cancer
Protocol No
ASTELLAS-2138-CL-0101
Categories
A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis or Myelodysplastic Syndrome and Anemia
Objective
Phase 1-2 DISC-0974 in Myelofibrosis and Anemia
Protocol No
DISC-0974-102
Categories
A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination with Deruxtecan Antibody-drug Conjugates in Subjects with Solid Tumors
Objective
A Phase 1B Study of Valemetostat in Combination with Deruxtecan in Patients with Solid Tumors
WITH DXd ADCs
WITH DXd ADCs
Protocol No
DAIICHI-DS3201-324
Categories
Phase II Single-Arm Study of Durvalumab and Bevacizumab Following Transarterial Radioembolization Using Yttrium-90 Glass Microspheres (TheraSphere) in Unresectable Hepatocellular Carcinoma Amenable to Locoregional Therapy
Objective
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)
Protocol No
AZ-D933GC00002-EMERALD-Y90
Categories